I'm of a different opinion. The FDA will want to see safety of our device. Therefore the number of DurAvr's will be similar to competitor trials ie 800-900. Trying to get 300 in a non inferiority trial is clever sneaky but doubt the FDA will allow such low DurAvrs numbers.
- Forums
- ASX - By Stock
- AVR
- Clinical trials
AVR
anteris technologies global corp.
Add to My Watchlist
4.91%
!
$5.03

Clinical trials, page-25
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.03 |
Change
-0.260(4.91%) |
Mkt cap ! $79.07M |
Open | High | Low | Value | Volume |
$5.22 | $5.35 | $5.03 | $114.8K | 22.35K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 330 | $5.03 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.10 | 100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 330 | 5.030 |
2 | 500 | 5.020 |
6 | 2500 | 5.000 |
1 | 20000 | 4.920 |
1 | 200 | 4.900 |
Price($) | Vol. | No. |
---|---|---|
5.100 | 100 | 1 |
5.330 | 500 | 1 |
5.340 | 1000 | 2 |
5.350 | 663 | 2 |
5.490 | 112 | 1 |
Last trade - 16.10pm 14/07/2025 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |